Show simple item record

dc.contributor.authorJukes, Zoë
dc.contributor.authorMorais, Goreti R.
dc.contributor.authorLoadman, Paul M.
dc.contributor.authorPors, Klaus
dc.date.accessioned2021-07-06T12:22:36Z
dc.date.accessioned2021-07-21T14:39:39Z
dc.date.available2021-07-06T12:22:36Z
dc.date.available2021-07-21T14:39:39Z
dc.date.issued2021-02
dc.identifier.citationJukes Z, Morais GR, Loadman PM and Pors K (2021) How can the potential of the duocarmycins be unlocked for cancer therapy? Drug Discovery Today. 26(2): 577-584.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18558
dc.descriptionnoen_US
dc.description.abstractThe duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure-activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.drudis.2020.11.020en_US
dc.subjectDuocarmycinsen_US
dc.subjectCancer therapyen_US
dc.subjectTherapeutic agentsen_US
dc.subjectProdrug approachesen_US
dc.subjectAntibody-directed technologiesen_US
dc.titleHow can the potential of the duocarmycins be unlocked for cancer therapy?en_US
dc.status.refereedyesen_US
dc.typeArticleen_US
dc.type.versionNo full-text in the repositoryen_US
dc.date.updated2021-07-06T11:22:38Z
refterms.dateFOA2021-07-21T14:40:10Z
dc.openaccess.statusNot Open Accessen_US


Item file(s)

Thumbnail
Name:
Zoe-main(1).pdf
Size:
718.6Kb
Format:
PDF
Description:
Keep suppressed - published version

This item appears in the following Collection(s)

Show simple item record